-
P646626-5mgPD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.In VivoPD-1-IN-24 (compound 1, 15mg/kg, PO, BID) exhibits TGI(%) of 19.96% in the subcutaneous 4T1 murine breast cancer model in BALB/c mice . PD-1-IN-24 (compound 1, 15mg/kg, PO, BID)
-
P654665-1mlPD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.In VivoPD-1-IN-24 (compound 1, 15mg/kg, PO, BID) exhibits TGI(%) of 19.96% in the subcutaneous 4T1 murine breast cancer model in BALB/c mice . PD-1-IN-24 (compound 1, 15mg/kg, PO, BID)
-
P659098-10mgPD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by
-
P659098-1mgPD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by
-
P659098-5mgPD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by
-
P648846-100mgPD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacyIn VitroPD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro
-
P648846-10mgPD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacyIn VitroPD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro
-
P648846-50mgPD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacyIn VitroPD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro
-
P648846-5mgPD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacyIn VitroPD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro
-
P655595-1mlPD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor ( IC 50 of 2.7 nM) with potent anticancer efficacyIn VitroPD-1/PD-L1-IN-10 (compound B2) significantly promotes interferongamma secretion in a dose-dependent manner in vitro
-
P659208-10mgPD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC 50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 + T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse
-
P659208-1mgPD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC 50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 + T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse